G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase III Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

G1 Therapeutics, Inc. announced that the last patient has been randomized in the Phase III clinical trial of trilaciclib for patients with metastatic colorectal cancer receiving chemotherapy.
[G1 Therapeutics, Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News